Close menu




September 14th, 2021 | 12:02 CEST

MorphoSys, HelloFresh, Aspermont - Price halving or rebound?

  • Investments
Photo credits: pixabay.com

Investors are likely to speculate on a rebound in the Valneva share in the coming days; because the price slide of over 30% on Monday was violent. Stifel analysts see sales and earnings estimates for 2020 and 2021 in jeopardy after the UK government unexpectedly canceled a major order for the COVID-19 vaccine under development. Investors have been waiting for a rebound in MorphoSys shares for some time. The latest analyst assessment gives little hope. If Bernstein Research has its way, HelloFresh could soon be down almost 50%. Aspermont seems ripe for a rebound - the share is interesting from a chart perspective, and analysts advise buying.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: MORPHOSYS AG O.N. | DE0006632003 , HELLOFRESH SE INH O.N. | DE000A161408 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    Aspermont: Ripe for a price increase in the short and long term

    Investors can speculate on a rebound in Aspermont Limited. The share of one of the world's leading providers of business-to-business (B2B) media for the commodities sector has slipped in recent days to the lower end of a sideways movement between AUD 0.022 and AUD 0.032, which has been stable for months. With a continuation of the trend, a good 30% price potential beckons. In the long term, even more, is possible. Thus, the German research house GBC analysts recommend the share of the Australian technology enterprise to the purchase (http://www.more-ir.de/d/22781.pdf). The price target is AUD 0.09. Aspermont publishes subscription-based content services for the mining, energy, agriculture and technology sectors worldwide. In business-to-business marketing, the Company is one of the leading players globally, GBC said. In fiscal 2020, Aspermont successfully completed its turnaround with positive EBITDA, it said. The Company is debt-free and has AUD 7.3 million in cash and cash equivalents.

    A new growth phase is now beginning for Aspermont, with 7.4 million contacts and a new lead generation program expected to boost the Company's gross margin and profit, it said. In addition, the current recipe for success should be applied to new areas. On this basis, GBC expects a profitable growth phase to begin in fiscal 2021, with revenue growth of 20% over the next two fiscal years. As a result, revenue would increase from AUD 15.20 million in 2020 to AUD 29.51 million in 2023. With this expected strong revenue momentum and economies of scale developing, gross margin should increase to 60%. EBITDA would then climb from AUD 3.03 million in 2020 to AUD 8.86 million. Based on the DCF model, GBC has published a price target of AUD 0.09 (EUR 0.06) for Aspermont shares. The price potential is thus considerable.

    HelloFresh: Analysts lower their thumbs

    The outlook for HelloFresh is less optimistic. At least, this is the opinion of the analysts at Bernstein Research, the HelloFresh share with "Underperform". The price target is EUR 51.50, well below the current level of around EUR 90. Analyst William Woods evaluated the past quarterly figures and the customer structure of the cooking box provider. His conclusion: the quality of the customer base is weak and characterized by high churn. He believes that the new DAX member will have a hard time meeting the high expectations. The cooking box provider itself expects significant growth in the coming years. To achieve this, however, it currently has to invest and expand capacity. That comes at the expense of margins. In the second quarter of the current year, this was not yet noticeable. In the three-month period, HelloFresh generated sales of around EUR 1.55 billion (Q2 2020: EUR 972 million), slightly more than analysts expected on average. Adjusted EBITDA was slightly above analysts' estimates of EUR 155 million at EUR 158 million (Q2 2020: EUR 154 million). For the full year 2021, the Company has raised its revenue forecast from 35-45% to 45-55%. Due to the accelerated expansion of production capacities, fulfillment costs in the current year are expected to be higher than initially assumed. Accordingly, the adjusted EBITDA margin for the full year 2021 is likely to be between 8.25% and 10.25%. Originally, 10% to 12% had been planned.

    MorphoSys: No sign of a rebound

    Investors are waiting in vain for a rebound at MorphoSys. Product sales of the cancer drug Monjuvi are below expectations, and the billion-dollar acquisition of Constellation Pharmaceuticals is weighing on the stock. As a result, the share has developed a clear downward trend in recent months. But even at the current level, Goldman Sachs, for example, sees no upside potential.

    The US investment bank has reinstated MorphoSys in its coverage. The share is currently only rated as "Neutral". The price target of EUR 42 is only at the current level. The acquisition of Constellation Pharmaceuticals would strengthen MorphoSys's previously thin research pipeline, provide medium- and long-term sales potential, and reduce the dependence on the hopeful Monjuvi. However, the high acquisition costs would further delay the achievement of profitability.


    Investors need to be patient with MorphoSys. HelloFresh has performed very well, and as Bernstein's study shows, the potential for a setback is high. If Aspermont stays in the trend channel, 20% to 30% price gains are possible, perhaps more in the long term.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read